Literature DB >> 17135358

Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G.

Zuoxiang Xiao1, Elana Ehrlich, Kun Luo, Yong Xiong, Xiao-Fang Yu.   

Abstract

APOBEC3 proteins are cellular antiviral proteins that are targeted for proteasomal degradation by primate lentiviral Vif proteins. Vif acts as a substrate receptor for the Cullin5 (Cul5) E3 ubiquitin ligase, specifically interacting with Cul5 through a novel H-(x5)-C-(x17-18)-C-(x3-5)-H zinc binding motif. Using the membrane-permeable zinc chelator, N,N,N',N'-tetrakis-(2-pyridylmethyl) ethylenediamine (TPEN), we demonstrated a requirement for zinc for Vif function in vivo. Treatment with TPEN at an IC50 of 1.79 microM inhibits Cul5 recruitment and APOBEC3G (A3G) degradation. Zinc chelation prevented Vif function in infectivity assays, allowing the virus to become sensitive to the antiviral activity of A3G. Zinc chelation had no effect on cellular Cul5-SOCS3 E3 ligase assembly, suggesting that zinc-dependent E3 ligase assembly may be unique to HIV-1 Vif, representing a new target for novel drug design.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17135358     DOI: 10.1096/fj.06-6773com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  59 in total

Review 1.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

2.  HIV-1 Vif interaction with APOBEC3 deaminases and its characterization by a new sensitive assay.

Authors:  Iris Cadima-Couto; Nuno Saraiva; Ana Catarina C Santos; Joao Goncalves
Journal:  J Neuroimmune Pharmacol       Date:  2011-01-29       Impact factor: 4.147

3.  The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.

Authors:  Mawuena Binka; Marcel Ooms; Myeika Steward; Viviana Simon
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

4.  Dissection of the HIV Vif interaction with human E3 ubiquitin ligase.

Authors:  Leslie S Wolfe; Bradford J Stanley; Chang Liu; William K Eliason; Yong Xiong
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

5.  Identification of a Cullin5-ElonginB-ElonginC E3 complex in degradation of feline immunodeficiency virus Vif-mediated feline APOBEC3 proteins.

Authors:  Jiawen Wang; Wenyan Zhang; Mingyu Lv; Tao Zuo; Wei Kong; Xianghui Yu
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

6.  Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.

Authors:  Erez Pery; Ann Sheehy; N Miranda Nebane; Andrew Jay Brazier; Vikas Misra; Kottampatty S Rajendran; Sara J Buhrlage; Marie K Mankowski; Lynn Rasmussen; E Lucile White; Roger G Ptak; Dana Gabuzda
Journal:  J Biol Chem       Date:  2015-02-27       Impact factor: 5.157

7.  Depletion of intracellular zinc inhibits the ubiquitin ligase activity of viral regulatory protein ICP0 and restricts herpes simplex virus 1 replication in cell culture.

Authors:  Kyle Grant; Louise Grant; Lily Tong; Chris Boutell
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

Review 8.  Advances in the structural understanding of Vif proteins.

Authors:  Pierre Barraud; Jean-Christophe Paillart; Roland Marquet; Carine Tisné
Journal:  Curr HIV Res       Date:  2008-03       Impact factor: 1.581

9.  Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly.

Authors:  Bradford J Stanley; Elana S Ehrlich; Leslie Short; Yunkai Yu; Zuoxiang Xiao; Xiao-Fang Yu; Yong Xiong
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

Review 10.  Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.

Authors:  Jessica L Smith; Wei Bu; Ryan C Burdick; Vinay K Pathak
Journal:  Trends Pharmacol Sci       Date:  2009-12       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.